Curriculum Vitae

Name	**First Name**	Youngkeun	**Last Name**	Ahn
Country	Gwangju, Republic of Korea			
Affiliation	Chonnam National University Hospital / Chonnam National University Medical School			

Educational Background

1983.03-1989.02: Chonnam National University Medical School, Medicine, MD
1992.03-1998.02: Chonnam National University, Cardiology, PhD
2000.09-2002.09: Massachusetts General Hospital, Harvard University, Gene and cell therapy, Post-doc

Professional Career

1998- : Clinical Instructor, Assistant, Associate, Full Professor of Department of Cardiology, Chonnam National University Hospital, Chonnam National University Medical School
2012-2015: Director, Regional Cardiocerebrovascular Center
2014- : Member (Medical Sciences) of the Korean Academy of Science and Technology
2014-2016: Vice-Director, Clinical Departments, Chonnam National University Hospital
2016-2017: Director of Planning and Coordination, Chonnam National University Hospital
2018- : Member of the National Academy of Medicine of Korea
2018-2021: Chairman of Korean Working Group of Basic Cardiovascular Sciences, The Korean Society of Cardiology
2020-2024: President & CEO, Chonnam National University Hospital
2022- : Chairman, Korean Society on Thrombosis and Hemostasis
2024- : President, Korean Society of Interventional Cardiology

Research Field

1. Acute myocardial infarction and heart failure
2. Developing a number of techniques of gene and cell therapy for preventing pathologic cardiac remodeling and atherosclerosis
3. Critical roles of macrophages in developing cardiac fibrosis
4. Patient-derived cardiac organoids for understanding heart disease, disease modeling, drug testing, toxicity screening, and precision medicine

Papers, Books, etc. presented or published by your name

1. Immediate versus staged complete revascularisation during index admission in patients with ST-segment elevation myocardial infarction and multivessel disease (OPTION-STEMI): a multicentre, non-inferiority, open-label, randomised trial. **Lancet**. 2025;406:1032-1043 (IF = 202.731, **Corresponding**)

2. Complete revascularisation timing in ST-segment elevation myocardial infarction and multivessel disease with heart failure: the OPTION-STEMI trial. **Eur Heart J** (IF = 39.855, **Corresponding**). 2025 in press.

3. ANGPTL4 Prevents Atherosclerosis by Preserving KLF2 to Suppress EndMT and Mitigates Endothelial Dysfunction. **Arterioscler Thromb Vasc Biol**. 2025;45:1742-1761 (IF = 10.514, **Corresponding**)

4. Preventive percutaneous coronary intervention for non-flow-limiting vulnerable atherosclerotic coronary plaques in diabetes: the PREVENT trial. **Eur Heart J**. 2025;46:3181-3197 (IF = 39.855, **Corresponding**)

5. IKKε-deficient macrophages impede cardiac repair after myocardial infarction by enhancing the macrophage-myofibroblast transition. **Exp Mol Med**. 2024;56:2052-2064 (IF = 12.172, **Corresponding**)

6. Early Left Ventricular Unloading or Conventional Approach After Venoarterial Extracorporeal Membrane Oxygenation: The EARLY-UNLOAD Randomized Clinical Trial. **Circulation**. 2023;148:1570-1581 (IF = 39.918, **Corresponding**)

7. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. **LANCET**. 2021;398:1305-1316 (IF = 202.731, **Corresponding**)